Details for Patent: 8,642,076

Which drugs does patent 8,642,076 protect, and when does it expire?

Patent 8,642,076 protects ONPATTRO and is included in one NDA.

This patent has thirty-two patent family members in eleven countries.

Summary for Patent: 8,642,076

Title:	Lipid containing formulations
Abstract:	Compositions and methods useful in administering nucleic acid based therapies, for example association complexes such as liposomes and lipoplexes are described.
Inventor(s):	Manoharan; Muthiah (Cambridge, MA), Rajeev; Kallanthottathil G. (Cambridge, MA), Akinc; Akin (Cambridge, MA), Jayaprakash; Narayanannair K. (Cambridge, MA), Jayaraman; Muthusamy (Cambridge, MA), Maier; Martin (Cambridge, MA)
Assignee:	Tekmira Pharmaceuticals Corporation (Burnaby, British Columbia, unknown)
Application Number:	13/211,094
Patent Claim Types: see list of patent claims	Compound;

Drugs Protected by US Patent 8,642,076

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Alnylam Pharms Inc	ONPATTRO	patisiran sodium	SOLUTION;INTRAVENOUS	210922-001	Aug 10, 2018		RX	Yes	Yes			Y

International Family Members for US Patent 8,642,076

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2007303205
Canada	2665225
Canada	2848238
Canada	2927045
Canada	3144493